Troxacitabine (BioDeep_00000855595)
代谢物信息卡片
Troxacitabine
化学式: C8H11N3O4 (213.0749526)
中文名称: 4-氨基-1-[(2S)-2-(羟甲基)-1,3-二氧杂环戊-4-基]嘧啶-2-酮
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1C(OC(O1)CO)N2C=CC(=NC2=O)N
InChI: InChI=1S/C8H11N3O4/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m0/s1
描述信息
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
D000970 - Antineoplastic Agents
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:134886
- KEGGdrug: D06255
- PubChem: 454194
- DrugBank: DB04961
- ChEMBL: CHEMBL359164
- CAS: 145918-75-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jeffrey J Dunmire, Rachida Bouhenni, Michael L Hart, Bassam T Wakim, Anthony M Chomyk, Sarah E Scott, Hiroshi Nakamura, Deepak P Edward. Novel serum proteomic signatures in a non-human primate model of retinal injury.
Molecular vision.
2011 Mar; 17(?):779-91. doi:
NULL. [PMID: 21527995] - Chia-Chi Lin, Muralidhar Beeram, Eric K Rowinsky, Chris H Takimoto, Chee M Ng, Charles E Geyer, Louis J Denis, Johann S De Bono, Desiree Hao, Anthony W Tolcher, Sun-Young Rha, Jacques Jolivet, Amita Patnaik. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology.
2009 Dec; 65(1):167-75. doi:
10.1007/s00280-009-1020-y. [PMID: 19449006] - Jianmin Wang, Shuqing Lü, Jianmin Yang, Xianmin Song, Li Chen, Chongmei Huang, Jun Hou, Weiping Zhang. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
Journal of hematology & oncology.
2009 Jul; 2(?):32. doi:
10.1186/1756-8722-2-32. [PMID: 19642997] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Anxun Wang, Su Li. Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect.
BMC biotechnology.
2008 May; 8(?):46. doi:
10.1186/1472-6750-8-46. [PMID: 18454874] - A Jimeno, W A Messersmith, C K Lee, W W Ma, D Laheru, R C Donehower, S D Baker, M Hidalgo. Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology.
2008 Feb; 19(2):374-9. doi:
10.1093/annonc/mdm572. [PMID: 18245131] - Keyvan Rezaï, François Lokiec, Isabelle Grandjean, Sophie Weill, Patricia de Cremoux, Vincent Bordier, Richard Ekue, Mickael Garcia, Marie-France Poupon, Didier Decaudin. Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.
BMC pharmacology.
2007 Oct; 7(?):13. doi:
10.1186/1471-2210-7-13. [PMID: 17963518] - Gail J Roboz, Francis J Giles, Ellen K Ritchie, Sandra Allen-Bard, Tania J Curcio, Meredith A Wilkes, S Lani Park, Hagop M Kantarjian, Stefan Faderl, Farhad Ravandi, Michael J Kelner, Eric J Feldman. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2007 Jan; 25(1):10-5. doi:
10.1200/jco.2006.06.6209. [PMID: 17146106] - Carlton K K Lee, Eric K Rowinsky, Jing Li, Francis Giles, Malcolm J Moore, Manuel Hidalgo, Edmund Capparelli, Jacques Jolivet, Sharyn D Baker. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2006 Apr; 12(7 Pt 1):2158-65. doi:
10.1158/1078-0432.ccr-05-2249. [PMID: 16609029] - Henriette Gourdeau, Lorraine Leblond, Bettina Hamelin, Kelly Dong, France Ouellet, Chantal Boudreau, Dominique Custeau, Annie Richard, Marie-Josée Gilbert, Jacques Jolivet. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2004 Nov; 10(22):7692-702. doi:
10.1158/1078-0432.ccr-04-0657. [PMID: 15570003] - C A Townsley, K Chi, D S Ernst, K Belanger, I Tannock, G A Bjarnason, D Stewart, R Goel, J D Ruether, L L Siu, J Jolivet, L McIntosh, L Seymour, M J Moore. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2003 Apr; 21(8):1524-9. doi:
10.1200/jco.2003.03.057. [PMID: 12697876] - Johann S de Bono, Joseph Stephenson, Sharyn D Baker, Manuel Hidalgo, Amita Patnaik, Lisa A Hammond, Geoffrey Weiss, Andrew Goetz, Lillian Siu, Cecelia Simmons, Jacques Jolivet, Eric K Rowinsky. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2002 Jan; 20(1):96-109. doi:
10.1200/jco.2002.20.1.96. [PMID: 11773159] - F J Giles, J E Cortes, S D Baker, D A Thomas, S O'Brien, T L Smith, M Beran, C Bivins, J Jolivet, H M Kantarjian. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2001 Feb; 19(3):762-71. doi:
10.1200/jco.2001.19.3.762. [PMID: 11157029] - L L Siu, G Attardo, E Izbicka, R Lawrence, C Cerna, L Gomez, K Davidson, C Finkle, C Marsolais, E K Rowinsky, D D Von Hoff. Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.
Annals of oncology : official journal of the European Society for Medical Oncology.
1998 Aug; 9(8):885-91. doi:
10.1023/a:1008387019062. [PMID: 9789612] - S A Kadhim, T L Bowlin, W R Waud, E G Angers, L Bibeau, J M DeMuys, K Bednarski, A Cimpoia, G Attardo. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
Cancer research.
1997 Nov; 57(21):4803-10. doi:
NULL. [PMID: 9354442] - L E Moore, F D Boudinot, C K Chu. Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats.
Cancer chemotherapy and pharmacology.
1997; 39(6):532-6. doi:
10.1007/s002800050609. [PMID: 9118465]